Sulfonylureas, Thiazolidinediones and DPP-4 Inhibitors
On this page
Direct answer
Sulfonylureas, thiazolidinediones and DPP-4 inhibitors are established oral glucose-lowering classes that differ mainly in hypoglycaemia, weight, fluid retention and heart-failure risk. Sulfonylureas close pancreatic beta-cell K-ATP channels and cause hypoglycaemia and weight gain. Thiazolidinediones act on PPAR-gamma and cause fluid retention and fractures, while DPP-4 inhibitors prolong incretin action with a low hypoglycaemia risk.
What you must remember
- Sulfonylureas: close beta-cell K-ATP channels to increase insulin secretion, and their main hazard is prolonged hypoglycaemia, often with weight gain.
- Glibenclamide caution: long-acting active metabolites accumulate in CKD and in older adults, so glibenclamide is avoided and gliclazide is generally preferred.
- Thiazolidinediones: pioglitazone acts on PPAR-gamma to improve insulin sensitivity and causes oedema, weight gain and fractures in women.
- Heart failure: thiazolidinediones are avoided in symptomatic heart failure because fluid retention can precipitate or worsen it.
- DPP-4 inhibitors: sitagliptin, vildagliptin, saxagliptin, linagliptin and alogliptin are weight-neutral, with a low hypoglycaemia risk on their own; saxagliptin and alogliptin carry a heart-failure caution.
- Angioedema: DPP-4 inhibitors combined with ACE inhibitors raise the reported risk of angioedema.
- Renal dosing: most DPP-4 inhibitors need dose reduction as eGFR falls; linagliptin is the exception because it is cleared mainly through bile.
Comparing the three classes
The three classes are often compared in patients with kidney disease, heart failure or a high risk of hypoglycaemia, and the differences below decide the choice. The table summarises the features most often tested in examinations.
| Feature | Sulfonylureas | Thiazolidinediones | DPP-4 inhibitors |
|---|---|---|---|
| Main action | Stimulate insulin release through K-ATP channels | Improve insulin sensitivity via PPAR-gamma | Prolong endogenous incretin action |
| Hypoglycaemia | Common and prolonged with long-acting drugs | Rare on their own | Rare on their own |
| Weight | Gain | Gain | Neutral |
| Key warning | Hypoglycaemia in older adults and CKD | Heart failure, fractures, bladder cancer signal | Angioedema with ACE inhibitors |
| Renal dosing | Gliclazide preferred; glibenclamide avoided | Generally no adjustment | Reduce dose as eGFR falls, except linagliptin |
The table shows that hypoglycaemia and weight drive the choice of a sulfonylurea, while heart failure and fluid retention drive the choice away from a thiazolidinedione. DPP-4 inhibitors are the weight-neutral, low-hypoglycaemia option, but they lower glucose less potently than most other agents.
Where the exam tries to catch you
Oral agent questions usually test the renal choice, the heart-failure contraindication or the drug interaction.
- Trap: choosing glibenclamide for an elderly patient with CKD. Correct: its active metabolites accumulate and cause prolonged hypoglycaemia, so gliclazide is the usual preferred sulfonylurea in this setting.
- Trap: giving pioglitazone to a patient with symptomatic heart failure. Correct: fluid retention can worsen heart failure, so thiazolidinediones are avoided in this setting.
- Trap: adding a DPP-4 inhibitor to an ACE inhibitor without considering angioedema. Correct: the combination raises the reported angioedema risk, so the patient is counselled to report lip, tongue or throat swelling.
Frequently asked questions
Why are sulfonylureas associated with prolonged hypoglycaemia in elderly patients with CKD?
Sulfonylureas stimulate insulin release largely independently of the prevailing glucose level, so hypoglycaemia can persist when they are cleared poorly. Long-acting agents such as glibenclamide carry active metabolites that accumulate in older adults and in chronic kidney disease. Gliclazide is generally preferred in these patients.
Why are thiazolidinediones avoided in heart failure?
Thiazolidinediones such as pioglitazone cause sodium and fluid retention, which can precipitate or worsen heart failure. Their labelling advises avoiding them in symptomatic heart failure. Fluid retention and fracture risk in women are the other reasons thiazolidinediones are used with caution.
Which DPP-4 inhibitor does not need renal dose adjustment?
Linagliptin does not need renal dose adjustment, because it is excreted mainly through bile rather than the kidney. Sitagliptin, vildagliptin and alogliptin require dose reduction as eGFR falls. The dose should always be checked against the current product label.
Why does an ACE inhibitor increase the risk of angioedema with a DPP-4 inhibitor?
ACE is a major enzyme that breaks down bradykinin, and DPP-4 inhibition has also been linked to raised bradykinin levels. Combining the two therefore increases the reported risk of angioedema. Patients should be told to seek urgent help for lip, tongue or throat swelling.